Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Subjects With Unresectable Malignant Mesothelioma
A phase 2 trial of Tremelimumab in mesothelioma, run by MedImmune LLC, active and no longer recruiting.
Overview
Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Subjects With Unresectable Malignant Mesothelioma is a phase 2 interventional study registered as NCT01843374 by MedImmune LLC, with 571 participants enrolled, started 2013-05-17 and due to reach its primary completion in 2016-01-24. Interventions recorded: Tremelimumab, Placebo. Conditions listed: Unresectable Pleural or Peritoneal Malignant Mesothelioma. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialDurvalumab Plus Tremelimumab as First-line Treatment in Chinese Patients With uHCC
Shares Tremelimumab, AstraZeneca.
- TrialDurvalumab and Tremelimumab as First Line Treatment in Participants With Advanced Hepatocellular Carcinoma (HCC)
Shares Tremelimumab, AstraZeneca.
- TrialDurvalumab and Tremelimumab for Pediatric Malignancies
Shares Tremelimumab, AstraZeneca.
- TrialA Study of Durvalumab or Tremelimumab Monotherapy, or Durvalumab in Combination With Tremelimumab or Bevacizumab in Advanced Hepatocellular Carcinoma
Shares Tremelimumab, AstraZeneca.
- TrialDurvalumab and Tremelimumab With Lenvatinib as First-line Treatment in Patients With Unresectable Hepatocellular Carcinoma
Shares Tremelimumab, AstraZeneca.
- TrialTreatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer Ineligible to Cisplatin or Who Refuse Cisplatin
Shares Tremelimumab, AstraZeneca.
- TrialPhase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma
Shares Tremelimumab, AstraZeneca.
- TrialStudy of MEDI4736 (Durvalumab) With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer
Shares Tremelimumab, AstraZeneca.